Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-19T10:48:09.282Z Has data issue: false hasContentIssue false

Plasma noradrenaline response to electroconvulsive therapy in depressive illness

Published online by Cambridge University Press:  03 January 2018

C. B. Kelly*
Affiliation:
Department of Mental Health, Queens University of Belfast
S. J. Cooper
Affiliation:
Department of Mental Health, Queens University of Belfast
*
Dr C. B. Kelly. Department of Mental Health, Whitla Medical Building, Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL

Abstract

Background

Abnormalities of catecholaminergic function have been hypothesised to cause depressive illness. Plasma noradrenaline can be used as a marker of central noradrenergic activity. It is of interest to examine the change in resting plasma noradrenaline in patients with depressive illness over a course of electroconvulsive therapy (ECT) and relate this to their clinical state.

Method

Patients referred for ECT who suffered from DSM – III – R major depressive disorder or dysthymia were recruited. Blood samples were taken before and after each treatment, during a course of ECT, to measure plasma noradrenaline and Cortisol. Clinical ratings were carried out weekly during the course of ECT.

Results

Plasma noradrenaline fell significantly in those patients with melancholic/psychotic depressions but increased in those with non-melancholic depressive illness. There was a strong trend indicating that a fall in plasma noradrenaline was associated with improvement in depression ratings in the melancholic/psychotic patients only.

Conclusions

Electroconvlusive therapy decreases plasma noradrenaline in melancholic/psychotic depressive illness and this shows a trend associated with clinical improvement.

Type
Papers
Copyright
Copyright © 1997 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM – III – R). Washington. DC: AFA.Google Scholar
Cooper, S. J., Kelly, J. K. & King, D. J. (1985) Adrenergic receptors in depression. British Journal of Psychiatry, 147, 2329.Google Scholar
Cooper, S. J., Kelly, C. B. & McCleMand, R. J. (1995) Affective disorders. 3: Electroconvulsive therapy. In Seminars in Clinical Psychopharmacology (ed. D. J. King), pp. 224258. London: Gaskell.Google Scholar
Danish University Antidepressant Group (1990) Paroxetine: A selective serotonin uptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicentre study. Journal of Affective Disorders, 18, 289299.Google Scholar
Gravenstein, J. S., Anton, A. H., Weiner, S. M., et al (1965) Catecholamine and cardiovascular response to electroconvulsive therapy in man. British Journal of Anaesthesia, 37, 833839.Google Scholar
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 5055.CrossRefGoogle ScholarPubMed
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of the Society of Clinical Psychology, 6, 278296.Google Scholar
Krstulovic, A. M., Dziedzic, S. W., Bertani-Dziedzic, L., et al (1981) Plasma catecholamines in hypertension and phaeochromocytoma determined using ion pair reverse phase chromatography with amperometric detection. Investigation of a separation mechanism and clinical methodology. Journal of Chromatography, 217, 523537.CrossRefGoogle Scholar
Lake, C. R., Pickar, D., Zeigler, M. G., et el (1982) High plasma norepinephrine levels in patients with major affective disorder. American Journal of Psychiatry, 139, 13151318.Google Scholar
Hann, J. J., Manevitz, A. Z., Chen, J. S., et al (1990a) Acute effects of single and repeated electroconvulsive therapy on plasma catecholamines and Wood pressure in major depressive disorder. Psychiatry Research, 34, 127137.Google Scholar
Hann, J. J., Mahler, J. C., Wilner, P. J., et al (1990b) Normalisation of blunted lymphocyte beta-adrenergic responsivity in melancholic inpatients by a course of electroconvulsive therapy. Archives of General Psychiatry, 47, 461464.Google Scholar
Nicholls, D. P., O'Connor, P. C., Harrow, D. W. G., et al (1984) Differential blockade of alpha-adrenoceptors by indoramin. British Journal of Clinical Pharmacology, 17, 719728.Google Scholar
Oldham, P. D. (1968) Measurement in medicine. The Interpretation of Numerical Disorder, pp. 198202. London: English University Press.Google Scholar
Roose, S. P., Glassman, A. H., Attia, E., et al (1994) Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry, 151, 17351739.Google Scholar
Roy, A., Picker, D., Linnoila, M., et al (1985) Plasma norepinephrine level in affective disorders. Archives of General Psychiatry, 42, 11811185.CrossRefGoogle ScholarPubMed
Roy, A., Picker, D., De Jong, J., et al (1988) Norepinephrine and its metabolites in cerebrospinal fluid, plasma and urine. Archives of General Psychiatry, 45, 849857.CrossRefGoogle ScholarPubMed
Schildkraut, J. J. (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry, 122, 509522.Google Scholar
Siever, L. J. & Davis, K. L. (1985) Overview: Toward a dysregulation hypothesis of depression. American Journal of Psychiatry, 142, 10171029.Google Scholar
Ziegler, H. G., Lake, C. R., Wood, J. H., et al (1976) Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood cerebrospinal fluid barrier for norepinephrine. Journal of Neurochemistry, 28, 677679.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.